Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.06.028 ◽

2021 ◽

Vol 16 (9) ◽

pp. 1426-1428

Author(s):

Bin-Chi Liao ◽

James Chih-Hsin Yang

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Antiangiogenesis Therapy ◽

Download Full-text

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Download Full-text

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Line Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib

Cancer Research ◽

10.1158/0008-5472.can-21-0556 ◽

2021 ◽

pp. canres.0556.2021

Author(s):

Lei Zhu ◽

Zhen Chen ◽

Hongjing Zang ◽

Songqing Fan ◽

Jiajia Gu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Third Generation ◽

Egfr Tyrosine Kinase Inhibitor ◽

The Third ◽

Egfr Tyrosine Kinase ◽

Download Full-text

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

OncoTargets and Therapy ◽

10.2147/ott.s62639 ◽

2014 ◽

pp. 799 ◽

Author(s):

Jeng-Sen Tseng ◽

Tsung-Ying Yang ◽

Kun-Chieh Chen ◽

Kuo-Hsuan Hsu ◽

Chong-Jen Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy ◽

Download Full-text

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor

Lung Cancer ◽

10.1016/j.lungcan.2014.09.008 ◽

2014 ◽

Vol 86 (2) ◽

pp. 219-224 ◽

Author(s):

Zhu Zeng ◽

Hong-hong Yan ◽

Xu-chao Zhang ◽

Wen-zhao Zhong ◽

Yan-yan He ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patient ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Lung Cancer Patient ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Chemotherapy Sensitivity ◽

Egfr Tyrosine Kinase ◽

Download Full-text

Dual-agent molecular targeting of growth factor receptors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-920152 ◽

2005 ◽

Vol 43 (05) ◽

Author(s):

A Hüther ◽

M Höpfner ◽

D Schuppan ◽

H Scherübl

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Hepatocellular Cancer ◽

Growth Factor Receptors ◽

Molecular Targeting ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Download Full-text

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Download Full-text

O-247 Molecular mechanisms of sensitivity and resistance to the HER1/EGFR-tyrosine kinase inhibitor erlotinib (Tarceva™)

Lung Cancer ◽

10.1016/s0169-5002(03)91905-2 ◽

2003 ◽

Vol 41 ◽

pp. S72 ◽

Author(s):

Roman Perez-Soler ◽

Qun Dai ◽

Yi-He Ling ◽

Marie Lee ◽

Glenn Kroog ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Molecular Mechanisms ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-11-0048 ◽

2011 ◽

Vol 10 (6) ◽

pp. 1102-1112 ◽

Author(s):

Monika E. Hegi ◽

Annie-Claire Diserens ◽

Pierre Bady ◽

Yuta Kamoshima ◽

Mathilde C. M. Kouwenhoven ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Pathway Analysis ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Preoperative Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text